Please login to the form below

Not currently logged in
Email:
Password:

Alunbrig

This page shows the latest Alunbrig news and features for those working in and with pharma, biotech and healthcare.

Pfizer files third-gen ALK inhibitor for lung cancer

Pfizer files third-gen ALK inhibitor for lung cancer

Meanwhile another new entrant - Alunbrig (brigatinib) from Takeda - is also making headway after its first approval in 2017, making $13m by the end of the calendar year.

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics